FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVA
-------------

OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Ivanic and Address of Reporting Ferson			2. Issuer Name and Ticker or Trading Symbol BioRestorative Therapies, Inc. [BRTX]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
ALSTODT LANCE			,—————————————————————————————————————	X	Director	10% Owner		
(Last)	(First)	(Middle)		X	Officer (give title below)	Other (specify below)		
C/O BIORESTORATIVE THERAPIES, INC. 40 MARCUS DRIVE, SUITE 1		,	3. Date of Earliest Transaction (Month/Day/Year) 11/04/2021		President, CEO, COB			
(Street) MELVILLE	NY	11747	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indivi	dual or Joint/Group Filing (Cher Form filed by One Reporting Form filed by More than One	Person		
(City)	(State)	(Zip)						

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transac Code (li 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported		7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock								151,418(1)(2)	D	

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (li 8)		Derivativ Securitie (A) or Dis	Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		9. Number of derivative Securities Beneficially Owned Following	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Reported Transaction(s) (Instr. 4)		
Stock Option	\$47.6	11/04/2021		D			293,479 <sup>(2)</sup>	(3)	03/18/2031	Common Stock	293,479(2)	\$0 <sup>(5)</sup>	0	D	
Stock Option	\$13.5	11/04/2021		A		293,479		(4)	03/18/2031	Common Stock	293,479	\$0 <sup>(5)</sup>	293,479	D	
Stock Option	\$13.5	11/04/2021		A		42,059		(6)	11/04/2031	Common Stock	42,059	\$0	42,059	D	

#### **Explanation of Responses:**

- 1. Includes 146,740 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 48,914 shares on March 18, 2022 and 48,913 shares on each of March 18, 2023 and March 18, 2024.
- 2. Reflects a 1-for-4,000 reverse split effected by the issuer on October 27, 2021.
- 3. The option vests to the extent of 146,740 shares on March 18, 2021, 73,370 shares on March 18, 2022 and 73,369 shares on March 18, 2023.
- 4. The option vests and becomes exercisable to the extent of 146,740 shares on March 18, 2021, 36,684 shares on November 4, 2021 with the remaining 110,055 shares in six nearly equal quarterly installments beginning December 18, 2021 and continuing every three months thereafter until fully vested.
- 5. The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option with an adjusted exercise price and vesting dates.
- 6. The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 with the remaining 21,029 shares vesting quarterly in eight nearly equal installments beginning on November 4, 2022.

/s/ Lance Alstodt

11/08/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.